TABLE 1.
Summary of bevacizumab phase III clinical trial.
| Study | Setting | N | Treatment arm | PFS (median, months) | PFS, HR (95% CI) | OS (median, months) | OS, HR (95% CI) | Ref |
|---|---|---|---|---|---|---|---|---|
| NCT01239732 ROSiA | Stage IIB to IV or Grade 3 Stage I to IIA OC | 1,021 | Bevacizumab + paclitaxel + carboplatin | 25.5 (23.7 to 27.6) | - | - | - | Oza et al. (2017) |
| NCT00976911 AURELIA | Patients with platinum-resistant EOC | 361 | Ⅰ: Paclitaxel/topotecan/liposomal doxorubicin | 3.4 (2.10 to 3.75) | - | 13.3 (11.89 to 16.43) | - | Pujade-Lauraine et al. (2014) |
| Ⅱ: Paclitaxel/topotecan/liposomal doxorubicin + bevacizumab | 6.8 (5.62 to 7.79) | 0.48 (0.38 to 0.60, p < 0.001) | 16.6 (13.70 to 18.99) | 0.85 (0.66 to 1.08, p = 0.174) | ||||
| NCT00434642 OCEANS | Patients with platinum-sensitive recurrent OC | 484 | Ⅰ: Carboplatin + gemcitabine + bevacizumab | 12.4 (11.40 to 12.71) | 0.484 (0.388 to 0.605, p < 0.0001) | 33.6 (30.32 to 35.84) | 0.952 (0.771 to 1.176, p = 0.65) | Aghajanian et al. (2015) |
| Ⅱ: Carboplatin + gemcitabine + placebo | 8.4 (8.31 to 9.66) | - | 32.9 (29.80 to 37.68) | - | ||||
| NCT00951496 GOG-252 | Stage II-III EOC | 1,560 | Ⅰ: Paclitaxel, IV + bevacizumab, IV + carboplatin, IV | 24.9 (22.3 to 27.2) | - | 75.4 (67.1 to NA) | - | (Walker et al. (2019)) |
| Ⅱ: Paclitaxel, IV + bevacizumab, IV + carboplatin, IP | 27.4 (24.6 to 28.8) | 0.94 (0.81 to 1.09) | 74.2 (61.9 to 78.4) | - | ||||
| III: Paclitaxel, IP + bevacizumab, IV + carboplatin, IP | 26.2 (23.8 to 28.0) | 0.99 (0.86 to 1.15) | 67.6 (63.5 to 74.6) | - | ||||
| NCT00262847 GOG-0218 | Newly diagnosed, untreated stage III or IV EOC | 1873 | Ⅰ: Placebo + paclitaxel + carboplatin | 10.3 | - | 39.3 | - | |
| Ⅱ: Paclitaxel + carboplatin + bevacizumab throughout | 14.1 | 0.717 (0.625 to 0.824, p < 0.001) | 39.7 | 0.915 (0.727 to 1.152, p = 0.45) | Burger et al. (2011) | |||
| Ⅲ: Paclitaxel + carboplatin + bevacizumab combination only | 11.2 | 0.908 (0.795 to 1.040, p = 0.16) | 38.7 | 1.036 (0.827 to 1.297, p = 0.76) | ||||
| NCT00483782 ICON7 | Newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer | 1,528 | Ⅰ: Paclitaxel + carboplatin | 22.4 | - | 28.8 | - | Perren et al. (2012) |
| Ⅱ: Paclitaxel + carboplatin + bevacizumab | 24.1 | 0.87 (0.77 to 0.99, p = 0.04) | 36.6 | 0.64 (0.48 to 0.85, p = 0.002) |